The decision follows a high-level review by the subject expert committee for vaccines, which raised an alarm over the safety ...
GSK (GSK) has agreed to buy US-listed biotech RAPT Therapeutics (US: RAPT) for $58 a share, valuing the company at about $2.2bn (£1.6bn), as it bolsters its respiratory and immunology pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results